Ocular aspects of myasthenia gravis

被引:73
|
作者
Barton, JJS
Fouladvand, M
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Human Vis & Eye Movement Lab, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Opthalmol,Human Vis & Eye Movement Lab, Boston, MA 02215 USA
[3] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA
关键词
ocular myasthenia; autoimmune disorder; diplopia; ptosis;
D O I
10.1055/s-2000-6829
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Ocular myasthenia gravis is a not uncommon autoimmune disorder causing diplopia, ptosis, and weakness of lid closure. The predilection of myasthenia for the ocular muscles may be related to differences between limb and extraocular muscles in either physiological function or antigenicity. Clinically ocular myasthenia can mimic any form of pupil-sparing ocular motility disorder. Dynamic abnormalities of myasthenic eye movements may reflect the primary hallmarks of the disease, which are fatigability and variability in strength, or secondary adaptive effects by the central nervous system, Tests to confirm the diagnosis include edrophonium challenge, repetitive nerve stimulation, single-fiber electromyography (EMG) of the frontalis, and assays for antibody directed against the acetylcholine receptor: all are less sensitive for ocular myasthenia than for generalized myasthenia. There is a higher incidence of other autoimmune conditions in myasthenia, notably thymoma and thyroid dysfunction. The differential diagnosis includes other diseases of the neuromuscular junction, such as Lambert-Eaton syndrome and botulism. Treatment consists of symptomatic use of acetylcholinesterase inhibitors and immunosuppression with steroids or azathioprine. Between 50 and 70% of patients with ocular myasthenia will eventually develop generalized disease: there is some retrospective data that steroids or azathioprine may reduce this by about 75%. The role of thymectomy in ocular myasthenia remains unclear.
引用
收藏
页码:7 / 20
页数:14
相关论文
共 50 条
  • [21] Update on Ocular Myasthenia Gravis
    Smith, Stacy V.
    Lee, Andrew G.
    NEUROLOGIC CLINICS, 2017, 35 (01) : 115 - +
  • [22] Update on Ocular Myasthenia Gravis
    O'Hare, Meabh
    Doughty, Christopher
    SEMINARS IN NEUROLOGY, 2019, 39 (06) : 749 - 760
  • [23] OCULAR MYASTHENIA-GRAVIS
    VANDALEN, JTW
    VANMOURIKNOORDENBOS, AM
    OPHTHALMOLOGICA, 1985, 190 (03) : 176 - 176
  • [24] Treatment of Ocular Myasthenia Gravis
    Scott R. Haines
    Matthew J. Thurtell
    Current Treatment Options in Neurology, 2012, 14 : 103 - 112
  • [25] Exacerbation of ocular myasthenia gravis
    Sermeus, Loic
    Rickmann, Annekatrin
    Schlosser, Rosemarie
    Szurman, Peter
    Januschowski, Kai
    OPHTHALMOLOGE, 2020, 117 (06): : 571 - 574
  • [26] Ocular manifestations in myasthenia gravis
    Mattis, RD
    ARCHIVES OF OPHTHALMOLOGY, 1941, 26 (06) : 969 - 982
  • [27] Ophthaproblem - Ocular myasthenia gravis
    Baxter, S
    Sharma, S
    CANADIAN FAMILY PHYSICIAN, 2002, 48 : 1771 - +
  • [28] OCULAR MANIFESTATIONS OF MYASTHENIA GRAVIS
    TEICHMAN, B
    GREER, KC
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1948, 59 (01) : 55 - 58
  • [29] OCULAR MYASTHENIA-GRAVIS
    MARCH, GA
    JOHNSON, LN
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 1993, 85 (09) : 681 - 684
  • [30] Pure Ocular Myasthenia gravis
    Kirzinger, Lukas
    Schotz, Sophie
    Schalke, Berthold
    AKTUELLE NEUROLOGIE, 2018, 45 (04) : 278 - 282